U.K. Pharmaceutical company to seek FDA approval for CBD based drug
There has been a lot of progress discovering how marijuana's cannabinoids can be used as medicine, especially cannabidiol, otherwise known as CBD. One of the leaders in this research is U.K. drug developer GW Pharmaceuticals (NASDAQ:GWPH). GW Pharmaceuticals already sells a THC derived drug in Europe.
According to three separate scientifically controlled trials performed last year (see here), GW Pharmaceutical's purified CBD, Epidiolex, reduces seizures by 40% in patients with Dravet and Lennox-Gastaut syndrome. These findings support that CBD with extremely low THC content helps provide relief to epilepsy patients. FDA approval would likely convince doctors who are otherwise hesitant to recommend medical marijuana to prescribe it.